Our Clinical Programs
The following are clinical trials currently underway by NanOlogy. In addition, NanOlogy has competed a Phase 1 clinical trial in peritoneal malignancies, a Phase 1/2 trial in prostate cancer, and a Phase 1/2 trial in actinic keratosis. In 2019, NanOlogy plans a follow-on prostate cancer clinical trial, as well as clinical trials in renal and lung cancers. Clinical trials in progress:

Pancreatic Cancer

Pancreatic Cyst

Ovarian Cancer

Bladder Cancer

Cutaneous Metastases

Current Clinical Trials of NanoPac® (sterile nanoparticle paclitaxel) for Suspension

Target:
Pancreatic Cancer

Now Recruiting

Trial of NanoPac® in Patients With Locally Advanced Pancreatic Adenocarcinoma

This trial evaluates the safety, tolerability, and preliminary efficacy of NanoPac® (sterile submicron particle paclitaxel suspension) injected intratumorally via endoscope-guided fine needle injection into patients with locally advanced pancreatic adenocarcinoma.

Four sites in the U.S. are currently participating. If you are over 18 and have been diagnosed with locally advanced pancreatic adenocarcinoma you may qualify for this study.

Study Locations and Contacts:

Baylor College of Medicine, Houston, TX.  Contact: Nichole Stewart, 713-798-0960, nlstewar@bcm.edu
Parkview Cancer Institute, Fort Wayne, IN.  Contact: Christina Zelt, 260-266-4153, christina.zelt@parkview.com
Cedars Sinai Medical Center, Los Angeles, CA.  Contact: Liliana Claudia Bancila, 310-423-3872, liliana.bancila@cshs.org
Texas Tech University HSC, El Paso, TX.  Contact: Nancy Casner, 915-525-5822, nancy.casner@utthsc.edu

More Trial Information

Target:
Pancreatic Mucinous-Cystic Neoplasm

Now Recruiting

Trial Evaluating Escalating Doses and the Safety of Intracystic Injection of NanoPac in Subjects With Mucinous Cystic Pancreatic Neoplasms

This trial evaluates the safety, tolerability, and preliminary efficacy of NanoPac® (sterile submicron particle paclitaxel suspension) injected intracystically into patients with mucinous pancreatic cysts via endoscope-guided fine needle injection following aspiration of the cyst during the same procedure.

Three sites in the U.S. are currently participating.  If you are over 18 and have a mucinous pancreatic cyst you may qualify for this study.

Study Locations and Contacts:

Baylor College of Medicine, Houston, TX.  Contact:  Aziz Tabash, 713-798-5765, abdalaziz.tabash@bcm.edu
University of Chicago Medicine, Chicago, IL.  Contact: Kianoush Donboli, 773-926-8490, kdonboli@medicine.bsd.uchicago.edu
Parkview Cancer Institute, Fort Wayne, IN.  Contact: Christina Zelt, 260-266-4153, christina.zelt@parkview.com

More Trial Information

Target:
Ovarian Cancer

Active, Not Recruiting

Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer

This trial evaluates the safety, tolerability, and preliminary efficacy of NanoPac® (sterile submicron particle paclitaxel suspension) administered intraperitoneally (IP) at the end of post-cytoreductive surgery, followed by standard of care (SOC) intravenous (IV) chemotherapy, in women with ovarian cancer.

Seven sites in the U.S. are participating.  If you are over 18 and have been diagnosed with epithelial ovarian cancer you may qualify for this study.

For more information regarding this trial, please email NANOPAC201601@usbiotest.com or call 1-805-595-1300.

Study Locations:

SUNY Downstate, Brooklyn, NY. 
Women & Infants Hospital of Rhode Island, Providence, RI. 
University of Texas Southwestern, Dallas, TX. 
University of Chicago, Chicago, IL. 
Greater Baltimore Medical Center, Baltimore, MD.
Magee-Women’s Hospital of UPMC, Pittsburg, PA.  
University of Minnesota, Minneapolis, MN.

More Trial Information

Current Clinical Trials of NanoDoce® (sterile nanoparticle docetaxel) for Suspension

Target:
Bladder Cancer

Not Yet Recruiting

Evaluation of NanoDoce® in Participants with Urothelial Carcinoma

This clinical trial is studying the administration of NanoDoce as a direct injection to the bladder wall immediately after tumor resection and as an intravesical instillation in an Induction and Maintenance schedule. Patients will be stratified into two treatment groups, Group 1 – non-muscle invasive bladder cancer (NMIBC) and Group 2 – muscle invasive bladder cancer (MIBC). All participants will receive NanoDoce, and will be evaluated for safety and tolerability, as well as the potential effects of NanoDoce on urothelial carcinoma.

Study Locations and Contacts:

Sites in the U.S. are currently undergoing initiation.
Contact:  Rose Marie Cavanna-Mast  805-595-1300  nanodoce201702@usbiotest.com

More Trial Information

Current Clinical Trials of Topical Submicron Particle Paclitaxel

Target:
Cutaneous Metastases

Now Recruiting

Study of Topical SOR007 Ointment for Cutaneous Metastases

This trial evaluates the safety, tolerability and preliminary efficacy of three concentrations of submicron particle paclitaxel anhydrous ointment (0.15%, 1.0%, and 2.0%) identified as SOR007 applied topically to patients with non-melanoma cutaneous metastases. Eligible lesions will be determined at baseline by the RECIST definition of measurable tumors (≥ 10mm in its longest diameter). The trial will include a dose escalation phase and a dose expansion phase.

Four sites in the U.S. are participating. If you are over 18 and have cutaneous metastasis originating from non-melanoma metastatic cancer you may qualify for this study.

Study Locations and Contacts:

University of Southern California, Los Angeles, CA.  Contact:  Julie E Lang, 323-422-8140 julie.lang@med.usc.edu
Sarcoma Oncology Center, Santa Monica, CA.  Contact: Victoria Chua, 310-201-6685, vchua@sarcomaoncology.com
Memorial Sloan Kettering Cancer Center, New York, NY.  Contact: Mario Lacouture, 646-888-6014, lacoutum@mskcc.org
Houston Methodist, Houston, TX.  Contact: Toniva Boone, 713-441-0686, tdboone@houstonmethodist.org

More Trial Information